WO2002034909A3 - Engineered chimera of hiv protein fragments and uses thereof - Google Patents

Engineered chimera of hiv protein fragments and uses thereof Download PDF

Info

Publication number
WO2002034909A3
WO2002034909A3 PCT/US2001/048040 US0148040W WO0234909A3 WO 2002034909 A3 WO2002034909 A3 WO 2002034909A3 US 0148040 W US0148040 W US 0148040W WO 0234909 A3 WO0234909 A3 WO 0234909A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein fragments
hiv protein
chimera
engineered
hiv
Prior art date
Application number
PCT/US2001/048040
Other languages
French (fr)
Other versions
WO2002034909A2 (en
Inventor
Kent D Stewart
Kevin R Steffy
Dale J Kempf
Kevin S Harris
Jeffrey R Huth
Vincent S Stoll
John E Harlan
Iok C Ng
Stephen F Betz
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP2002537879A priority Critical patent/JP2004528011A/en
Priority to EP01988771A priority patent/EP1379646A2/en
Priority to MXPA03003696A priority patent/MXPA03003696A/en
Priority to CA002427312A priority patent/CA2427312A1/en
Publication of WO2002034909A2 publication Critical patent/WO2002034909A2/en
Publication of WO2002034909A3 publication Critical patent/WO2002034909A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The subject invention encompasses novel proteins related to the human immunodeficiency virus (HIV-1) gp41 protein and to methods of use thereof. For example, the proteins may be utilized in the screening of anti-HIV compounds.
PCT/US2001/048040 2000-10-27 2001-10-26 Engineered chimera of hiv protein fragments and uses thereof WO2002034909A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002537879A JP2004528011A (en) 2000-10-27 2001-10-26 Engineered chimeras of protein fragments and methods of using the same
EP01988771A EP1379646A2 (en) 2000-10-27 2001-10-26 Engineered chimera of protein fragments and methods of use thereof
MXPA03003696A MXPA03003696A (en) 2000-10-27 2001-10-26 Engineered chimera of protein fragments and methods of use thereof.
CA002427312A CA2427312A1 (en) 2000-10-27 2001-10-26 Engineered chimera of protein fragments and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69831100A 2000-10-27 2000-10-27
US09/698,311 2000-10-27

Publications (2)

Publication Number Publication Date
WO2002034909A2 WO2002034909A2 (en) 2002-05-02
WO2002034909A3 true WO2002034909A3 (en) 2003-11-13

Family

ID=24804726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048040 WO2002034909A2 (en) 2000-10-27 2001-10-26 Engineered chimera of hiv protein fragments and uses thereof

Country Status (5)

Country Link
EP (1) EP1379646A2 (en)
JP (1) JP2004528011A (en)
CA (1) CA2427312A1 (en)
MX (1) MXPA03003696A (en)
WO (1) WO2002034909A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1860130B (en) 2003-07-30 2012-05-30 迈梅蒂克斯公司 New soluble and stabilized trimeric form of GP41 polypeptides
JP4551160B2 (en) * 2003-10-24 2010-09-22 株式会社島津製作所 Protein or peptide analysis method using labeled amidation
CN109406469B (en) * 2018-10-24 2021-04-09 中国医科大学 Method for detecting tryptophan based on protein binding induced DNA double-strand allosteric

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040616A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040616A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ECKERT D M ET AL: "INHIBITING HIV-1 ENTRY: DISCOVERY OF D-PEPTIDE INHIBITORS THAT TARGET THE GP41 COILED-COIL POCKET", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 99, no. 1, 1 November 1999 (1999-11-01), pages 103 - 115, XP000982264, ISSN: 0092-8674 *
JI HONG ET AL: "Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion.", JOURNAL OF VIROLOGY, vol. 73, no. 10, October 1999 (1999-10-01), pages 8578 - 8586, XP002231800, ISSN: 0022-538X *
JIANG SHIBO ET AL: "A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 12, December 1998 (1998-12-01), pages 10213 - 10217, XP002170629, ISSN: 0022-538X *
TAN KEMIN ET AL: "Atomic structure of a thermostable subdomain of HIV-1 gp41", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, no. 23, 11 November 1997 (1997-11-11), pages 12303 - 12308, XP002170631, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002034909A2 (en) 2002-05-02
MXPA03003696A (en) 2005-01-25
JP2004528011A (en) 2004-09-16
EP1379646A2 (en) 2004-01-14
CA2427312A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
MXPA02007478A (en) Human immunodeficiency virus vaccine.
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
EA200200724A1 (en) VACCINE FOR PREVENTION OR THERAPEUTIC IMMUNIZATION AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY (HIV)
WO1999010375A3 (en) Vaccine against hpv
DE60037450D1 (en) FUNF-HELIX PROTEIN
DE69632256D1 (en) ANTIVIRAL PROTEINS, CODING DNA, AND THEIR USE
WO2006013106A3 (en) Vaccine for prevention and treatment of hiv-infection
EA200801798A1 (en) VIROSOMOPROGABLE VESICULAS CONTAINING ANTIGENS DERIVED FROM GP41
PE20040554A1 (en) VACCINES INVOLVING FUSION PROTEINS
WO2002024149A3 (en) Immunogen comprising ligand bound hiv envelpe protein
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
WO2005080418A3 (en) Multimerised hiv fusion inhibitors
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
ATE295727T1 (en) USE OF CERTAIN SUBSTITUTED PYRROLIDONES SUCH AS PIRACETAM IN THE TREATMENT OF VIRAL AND OTHER DISEASES
WO2003015702A3 (en) Epitopes of human immunodeficiency virus-1
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2003052122A3 (en) Gp41 inhibitor
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2002020571A3 (en) Attenuated hiv strains and use thereof
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2006030323A3 (en) Compounds that inhibit replication of human immunodeficiency virus
WO2004031356A3 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003696

Country of ref document: MX

Ref document number: 2002537879

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2427312

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001988771

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001988771

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001988771

Country of ref document: EP